文章：

BAALC相关microRNA miR-3151的表达水平是细胞遗传学中危急性髓系白血病年轻患者的独立预后因素

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia

原文发布日期：2015-10-02

DOI: 10.1038/bcj.2015.76

类型: Original Article

开放获取: 是

英文摘要：

Acute myeloid leukemia (AML) is a heterogeneous disease whose prognosis is mainly related to the biological risk conferred by cytogenetics and molecular profiling. In elderly patients (⩾60 years) with normal karyotype AML miR-3151 have been identified as a prognostic factor. However, miR-3151 prognostic value has not been examined in younger AML patients. In the present work, we have studied miR-3151 alone and in combination with BAALC, its host gene, in a cohort of 181 younger intermediate-risk AML (IR-AML) patients. Patients with higher expression of miR-3151 had shorter overall survival (P=0.0025), shorter leukemia-free survival (P=0.026) and higher cumulative incidence of relapse (P=0.082). Moreover, in the multivariate analysis miR-3151 emerged as independent prognostic marker in both the overall series and within the unfavorable molecular prognostic category. Interestingly, the combined determination of both miR-3151 and BAALC improved this prognostic stratification, with patients with low levels of both parameters showing a better outcome compared with those patients harboring increased levels of one or both markers (P=0.003). In addition, we studied the microRNA expression profile associated with miR-3151 identifying a six-microRNA signature. In conclusion, the analysis of miR-3151 and BAALC expression may well contribute to an improved prognostic stratification of younger patients with IR-AML.

摘要翻译： 

急性髓系白血病（AML）是一种异质性疾病，其预后主要与细胞遗传学和分子谱分析所揭示的生物学风险相关。在核型正常的老年（≥60岁）AML患者中，miR-3151已被确认为预后因素，但其在年轻AML患者中的预后价值尚未得到验证。本研究在181例年轻中危AML（IR-AML）患者队列中，单独检测了miR-3151并联合其宿主基因BAALC进行综合分析。结果显示：miR-3151高表达患者的总生存期更短（P=0.0025）、无白血病生存期更短（P=0.026）、累积复发率更高（P=0.082）。多变量分析进一步表明，miR-3151在整个队列及不良分子预后亚组中均为独立预后标志物。值得注意的是，联合检测miR-3151与BAALC能优化预后分层——两项指标均低表达患者的预后显著优于单一或双指标高表达患者（P=0.003）。此外，通过分析miR-3151相关的微RNA表达谱，我们鉴定出包含六种微RNA的特征组合。综上，miR-3151与BAALC表达分析可显著提升年轻IR-AML患者的预后分层精准度。

原文链接：

The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia